Single photon-emission computed tomography imaging in early Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 8, Issue 12, 2008, Pages 1853-1864

  Antonini, Angelo ^a   Isaias, Ioannis U ^a  

^a PARKINSON INSTITUTE   (Italy)

Author keywords

Dopamine transporter; Essential tremor; Parkinson's disease; Perfusion tracer; SPECT

Indexed keywords

ALTROPANE I 123; BETA 2BETA CARBOMETHOXY 3 BETA (4 IODOPHENYL)TROPANE I 123; FLUOROPROPYL BETA 2BETA CARBOMETHOXY 3 BETA (4 IODOPHENYL)TROPANE I 123; IODINE 123; N (3 IODOPROPEN 2 YL) 2BETA CARBOMETHOXY 3 BETA (4 CHLOROPHENYL)TROPANE I 123; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG;

BRAIN PERFUSION; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; ESSENTIAL TREMOR; HEART PERFUSION; HUMAN; MONOAMINERGIC SYSTEM; NEUROPROTECTION; PARKINSON DISEASE; PARKINSONISM; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ESSENTIAL TREMOR; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 57749182221     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.12.1853     Document Type: Review

References (180)

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33-39 (1999).
2. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51, 745-752 (1988).
3. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. 5, 75-86 (2006).
4. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can. J. Neurol. Sci. 18, 275-278 (1991).
5. Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of the clinical diagnosis of Parkinson's disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181-184 (1992).
6. Mark MH, Sage JI, Dickson DW, Schwarz KO, Duvoisin RC. Levodopa-nonresponsive Lewy body parkinsonism: clinicopathologic study of two cases. Neurology 7, 1323-1327 (1992).
7. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson disease. Arch. Neurol. 50, 140-148 (1993).
8. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 28, 99-102 (1999).
9. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat. Disord. 13, 2-7 (2007).
10. Arvanitakis Z, Wilson RS, Schneider JA et al. Diabetes mellitus and progression of rigidity and gait disturbance in older persons. Neurology 63, 996-1001 (2004).
11. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 69, 1542-1550 (2007).
12. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3, 309-316 (2004).
13. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology 69, 1701-1711 (2007).
14. Delong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol. 64, 20-24 (2007).
15. Gonera EG, Van't Hof M, Berger HJ, Van Weel C, Horstink MW. Symptoms and duration of the premotor phase in Parkinson's disease. Mov. Disord. 12, 871-876 (1997).
16. Becker G, Müller A, Braune S et al. Early diagnosis of Parkinson's disease. J. Neurol. 3, 40-48 (2002).
17. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Nonmotor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 3, 235-245 (2006).
18. Chaudhuri KR, Martinez-Martin P. Quantitation of nonmotor symptoms in Parkinson's disease. Eur. J. Neurol. 15, 2-7 (2008).
19. Marras C, Lang A. Changing concepts in Parkinson disease: moving beyond the Decade of the Brain. Neurology 70, 1996-2003 (2008).
20. Abbott RD, Ross GW, White LR et al. Environmental, life-style and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia aging study. J. Neurol. 250, 30-39 (2003).
21. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24, 197-211 (2003).
22. Iranzo A. Molinuevo JL, Santamaría J et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 5, 572-577 (2006).
23. Braak H, Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 13, 16-25 (2008). • Reviews the concept of caudal-cranial progression of neurodegeneration in Parkinson's disease (PD).
24. Groenewegen HJ, Berendse HW. The specificity of the 'nonspecific' midline and intralaminar thalamic nuclei. Trends Neurosci. 17, 52-57 (1994).
25. Brooks DJ, Frey KA, Marek KL et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp. Neurol. 184, 68-79 (2003).
26. Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann. Neurol. 53, 110-118 (2003).
27. Marek K, Jennings D, Seibyl J. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann. Neurol. 53, 160-166 (2003).
28. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease. Mov. Disord. 18, 63-70 (2003).
29. Seibyl J, Jennings D, Tabamo R, Marek K. Neuroimaging trials of Parkinson's disease progression. J. Neurol. 251, 9-13 (2004).
30. Ravina B, Eidelberg D, Ahlskog JE et al. The role of radiotracer imaging in Parkinson disease. Neurology 64, 208-215 (2005).
31. Nestler J, Hyman SE, Malenka RC. Catecholamines. In: Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. Nestler EJ, Hyman SE Malenka RC (Eds). McGraw-Hill, NY, USA (2001).
32. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann. Neurol. 35, 494-498 (1994).
33. Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J. Comp. Neurol. 388, 211-227 (1997).
34. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 16, 436-447 (1996).
35. Bezard E, Dovero S, Prunier C et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21, 6853-6861 (2001).
36. Innis RB. Single photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease. Eur. J. Nucl. Med. 21, 1-5 (1994).
37. Innis RB, Seibyl JP, Scanley BE et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc. Natl Acad. Sci. USA 90, 11965-11969 (1993).
38. Seibyl JP. Single-photon emission computed tomography of the dopamine transporter in parkinsonism. J. Neuroimaging 9, 223-228 (1999).
39. Carroll FI, Scheffel U, Dannals RF et al. Development of imaging agents for the dopamine transporter. Med. Res. Rev. 15, 419-444 (1995).
40. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38, 589-598 (1995).
41. Seibyl JP, Marek K, Sheff K et al. Test/retest reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J. Nucl. Med. 38, 1453-1459 (1997).
42. Abi-Dargham A, Gandelman MS, DeErausquin GA et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J. Nucl. Med. 37, 1129-1133 (1996).
43. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur. J. Nucl. Med. 24, 68-71 (1997).
44. Goodman MM, Kung M-P, Kabalka GW et al. Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2β- carbomethoxy-3β-(4-chlorophenyl) tropanes: potential dopamine reuptake site imaging agents. J. Med. Chem. 37, 1535-1542 (1994).
45. Mozley PD, Stubbs JB, Kim H-J et al. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J. Nucl. Med. 37, 151-159 (1996).
46. 123I]IPT and single photon emission tomography. Eur. J. Nucl. Med. 24, 415-421 (1997).
47. Fischman AJ, Bonab AA, Babich JW et al. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 29, 128-141 (1998).
48. Madras BK, Meltzer PC, Liang AY et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 29, 93-104 (1998).
49. Seibyl JP, Marek K, Sheff K et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J. Nucl. Med. 39, 1500-1508 (1998).
50. 123I]-2 β-carbomethoxy-3 β-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J. Med. Chem. 34, 3144-3146 (1991).
51. 99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J. Nucl. Med. 41, 584-589 (2000).
52. 99mTc-TRODAT-1 imaging. J. Nucl. Med. 42, 1303-1308 (2001).
53. Tzen KY, Lu CS, Yen TC, Wey SP, Ting G. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m) Tc-TRODAT-1. J. Nucl. Med. 42, 408-413 (2001).
54. 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J. Nucl. Med. 45, 393-401 (2004).
55. 123I] FP-CIT SPECT in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur. J. Nucl. Med. 28, 266-272 (2001).
56. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J. Neural Transm. 38, 277-301 (1976).
57. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45, 19-34 (1987).
58. 123I] β-CIT SPECT. J. Neurol. 245, 14-20 (1998).
59. Tissingh G, Booij J, Bergmans P et al. Iodine-123-N-Vfluoropropyl-2β-carbomethoxy-3β-[4-iodophenyl]tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J. Nucl. Med. 39, 1143-1114 (1998).
60. 123I] β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57, 2089-2094 (2001).
61. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: SN regional selectivity. Brain 114, 2283-2301 (1991).
62. 18F] DOPA PET. J. Neurol. Neurosurg. Psychiatry 64, 314-319 (1998).
63. Berendse HW, Booij J, Francot CM et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann. Neurol. 50, 34-41 (2001).
64. Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54, 93-101 (2003).
65. Morrish PK. Real-PET and CONSORT. Ann. Neurol. 54, 692-693 (2003).
66. Marek K, Jennings D, Seibyl J. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 64, A274 (2005).
67. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287, 1653-1661 (2002).
68. 123I] FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J. Neural Transm. 108, 1011-1019 (2001).
69. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl. Med. Commun. 27, 933-937 (2006).
70. Parkinson Study Group PRECEPTS Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69, 1480-1490 (2007).
71. Antonini A, Isaias IU. Imaging evidence supports a link between essential tremor and Parkinson's disease. Nucl. Med. Comm. (2008) (In Press).
72. 123I]β-CIT and SPECT in essential tremor and Parkinson's disease. J. Neural Transm. 105, 1213-1228 (1998).
73. 123I] fluoropropyl-β-2β-carbomethoxy-3 β-(4-iodophenyl)tropane.
74. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol. 7, 27 (2007). •• Provides a review of current results on the use of single photon emission computed tomography (SPECT) in the differential diagnosis of parkinsonism
75. 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur. Neurol. 59, 258-266 (2008).
76. Isaias IU, Canesi M, Benti R et al. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl. Med. Commun. 29, 349-353 (2008).
77. 99mTc-TRODAT-1 SPECT study in early Parkinson's disease and essential tremor. Acta Neurol. Scand. 112, 380-385 (2005).
78. 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov. Disord. (2008) (Epub ahead of print).
79. 123I]- ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol. Sci. 24, 149-150 (2003).
80. 123I]-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 128, 1605-1612 (2005).
81. Zijlmans JCM, Daniel SE, Hughes AJ, Révész T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov. Disord. 19, 630-640 (2004).
82. Scherfler C, Schwarz J, Antonini A et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov. Disord. 22, 1229-1238 (2007).
83. 123]FP- CIT SPECT. Schizophr. Res. 47, 59-67 (2001).
84. 123I] FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov. Disord. 21, 510-514 (2006).
85. 123I] FP-CIT SPET imaging in drug induced parkinsonism. Mov. Disord. 23(13), 1825-1829 (2008).
86. 123I]-CIT SPECT. J. Neural Transm. 107, 543-552 (2000).
87. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl. Med. Commun. 22, 721-725 (2001).
88. 123I-FP-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging 32, 1176-1185 (2005).
89. 125I] IBZM: a potential CNS D-2 dopamine receptor imaging agent. Int. J. Rad. Appl. Instrum. 15, 195-201 (1988).
90. Laruelle M, Abi-Dargham A, van Dyck CH et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med. 36, 1182-1190 (1995).
91. Murphy RA, Kung HF, Kung MP, Billings J. Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents. J. Med. Chem. 33, 171-178 (1990).
92. Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent. J. Nucl. Med. 31, 648-654 (1990).
93. 123I- iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 42, 556-561 (1992).
94. Hierholzer J, Cordes M, Schelosky L et al. The differential diagnosis of Parkinson diseases-123I-IBZM-SPECT vs the apomorphine test. Rofo 159, 86-90 (1993).
95. Antonini A, Vontobel P, Psylla M et al. Complementary PET studies of the striatal dopaminergic system in Parkinson's disease. Arch. Neurol. 52, 1183-1192 (1995).
96. 123I]IBZM SPET study. Adv. Neurol. 69, 467-473 (1996).
97. Hierholzer J, Cordes M, Venz S et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J. Nucl. Med. 39, 954-960 (1998).
98. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur. J. Nucl. Med. 26, 171-182 (1999).
99. 123I-iodolisuride SPECT in degenerative extrapyramidal diseases. Nucl. Med. Commun. 22, 1207-1214 (2001).
100. Knudsen GM, Karlsborg M, Thomsen G et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur. J. Nucl. Med. Mol. Imaging 31, 1631-1638 (2004).
101. Buck A, Westera G, Sutter M et al. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. J. Nucl. Med. 36, 1196-1200 (1995).
102. Aarsland D, Karlsen K. Neuropsychiatric aspects of Parkinson's disease. Curr. Psychiatry Rep. 1, 61-68 (1999).
103. Antonini A. Unraveling depression in Parkinson's disease. Eur. J. Neurol. 15(9), 885-886 (2008).
104. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. 40, 288-295 (1994).
105. Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol. Psychiatry 5, 32-38 (2000).
106. Suehiro M, Scheffel UA, Ravert HT et al. Highly potent indanamine serotonin uptake blockers as radiotracers for imaging serotonin uptake sites. Nucl. Med. Biol. 21, 1083-1091 (1994).
107. Szabo Z, Kao PF, Scheffel U et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C] (+)MCN5652. Synapse 20, 37-43 (1995).
108. Szabo Z, Mohamadiyeh M, Scheffel U et al. Impulse-response function and kinetic-model of C-11-labeled (+) MCN5652. J. Nucl. Med. 37, 125 (1996).
109. Szabo Z, Scheffel U, Mathews WB et al. Kinetic analysis of [11C]McN5652. A serotonin transporter radioligand. J. Cereb. Blood Flow Metab. 19, 967-981 (1999).
110. Parsey RV, Kegeles LS, Hwang DR et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J. Nucl. Med. 41, 1465-1477 (2000).
111. Maryanoff EM, Vaught JL, Shank RP et al. Pyrroloisoquinoleines antidepressants. A focus on serotonin. J. Med. Chem. 33, 2793-2797 (1990).
112. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13, 295-309 (1993).
113. Kuikka JT, Bergstrom KA, Ahonen A et al. Comparison of iodine-123 labelled 2 β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur. J. Nucl. Med. 22, 356-360 (1995).
114. 123I]β-CIT binding to dopamine and serotonin transporters. Eur. J. Nucl. Med. 23, 431-436 (1996).
115. Tiihonen J, Kuikka JT, Bergstrom KA et al. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behavior. Eur. J. Nucl. Med. 24, 1253-1260 (1997).
116. 123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biol. Psychiatry 44, 1090-1098 (1998).
117. Meltzer CC, Smith G, DeKosky ST et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 18, 407-430 (1998).
118. Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol. Psychiatry 44, 534-549 (1998).
119. 123I]β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol. Psychiatry 47, 482-489 (2000).
120. 123I] β-CIT SPECT study. J. Neural Transm. 115, 721-729 (2008).
121. Bergstrom KA, Halldin C, Hall H et al. In vitro and in vivo characterization of nor-β-CIT: a potential radioligand for visualization of the serotonin transporter in the brain. Eur. J. Nucl. Med. 24, 596-601 (1997).
122. Blough BE, Abraham P, Mills AC et al. 3β-(4-ethyl-3- iodophenyl)nortropane-2 β-carboxylic acid methyl ester as a high-affinity selective ligand for the serotonin transporter. J. Med. Chem. 40, 3861-3864 (1997).
123. Hiltunen J, Akerman KK, Kuikka JT et al. Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. Eur. J. Nucl. Med. 25, 19-23 (1998).
124. 123I] IDAM, 5-iodo-2-((2-((dimethyl- amino)methyl)phenyl)thio) benzyl alcohol. J. Med. Chem. 42, 333-335 (1999).
125. Zhuang ZP, Choi SR, Hou C et al. A novel serotonin transporter ligand: (5-iodo-2-(2-di-methylaminomethylphenoxy)-benzyl alcohol (ODAM). Nucl. Med. Biol. 27, 169-175 (2000).
126. 123I]IDAM. Eur. J. Nucl. Med. 26, 854-861 (1999).
127. 123I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. Eur. J. Nucl. Med. 26, 844-853 (1999).
128. 123I[ADAM] in healthy controls: a selective SERT radioligand. Int. J. Neuropsychopharmacol. 10, 1-8 (2006).
129. 123I]ADAM: a SPECT validation study. Eur. J. Nucl. Med. Mol. Imaging 32, 1329-1336 (2005).
130. 123I] ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl.) 188, 263-272 (2006).
131. 123I]ADAM SPECT study. Psychopharmacology (Berl.) 191, 333-339 (2007).
132. 123I]INER. Bioorg. Med. Chem. Lett. 15, 533-537 (2007).
133. Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol. 6, 926-932 (2007).
134. Feigin A, Antonini A, Fukuda M et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov. Disord. 17, 1265-1270 (2002).
135. 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging 30, 16-24 (2003).
136. 99mTc-TRODAT-1. Eur. J. Nucl. Med. Mol. Imaging 31, 1119-1127 (2004).
137. Cilia R, Siri C, Marotta G et al. Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: an ECD-SPECT study. Parkinsonism Relat. Disord. 13, 290-294 (2007).
138. Antonini A, De Notaris R, Benti R et al. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol. Sci. 22, 45-46 (2001).
139. Antonini A, Benti R, Righini A, Pezzoli G. Sensitivity and specificity of ECD/SPECT and high field (1,5T) MRI in the differential diagnosis between MSA and Parkinson's disease. Neurology 52, S351 (1999). • Compares the specificity of imaging and MRI landmark signs in the differential diagnosis between PD and multiple system atrophy.
140. Derejko M, Slawek J, Wieczorek D, Brockhuis B, Dubaniewicz M, Lass P. Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment. Nucl. Med. Commun. 27, 945-951 (2006).
141. Chang CC, Liu JS, Chang YY, Chang WN, Chen SS, Lee CH. (99m)Tc-ethyl cysteinate dimer brain SPECT findings in early stage of dementia with Lewy bodies and Parkinson's disease patients: a correlation with neuropsychological tests. Eur. J. Neurol. 15, 61-65 (2008).
142. 123I-IMP-SPECT with the ARG method. Nippon Rinsho 55, 238-242 (2007).
143. Hayashi H, Odano I, Nishihara M, Higuchi S, Sakai K, Ishikawa A. Clinical evaluation of Parkinson's disease using 123I-IMP SPECT. Kaku Igaku 26, 1405-1415 (1989).
144. Kamei H, Nakajima T, Fukuhara N. Statistic rCBF study of extrapyramidal disorders. No To Shinkei 54, 667-672 (2002).
145. Matsui H, Udaka F, Miyoshi T et al. Brain perfusion differences between Parkinson's disease and multiple system atrophy with predominant parkinsonian features. Parkinsonism Relat. Disord. 11, 227-232 (2005).
146. Matsui H, Nishinaka K, Oda M et al. Heterogeneous factors in dementia with Parkinson's disease: IMP-SPECT study. Parkinsonism Relat. Disord. 13, 174-181 (2006).
147. Leenders KL. Significance of non-presynaptic SPECT tracer methods in Parkinson's disease. Mov. Disord. 18, 39-42 (2003).
148. 99mTc]-HM-PAO study. Eur. Neurol. 33, 143-148 (1993).
149. 123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders. Nuklearmedizin 33, 184-188 (1994).
150. Markus HS, Costa DC, Lees AJ. HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness. J. Neurol. Neurosurg. Psychiatry 57, 180-185 (1994).
151. 99Tcm- HMPAO SPECT in Parkinson's disease. Nucl. Med. Commun. 13, 744-748 (1992).
152. Wang SJ, Liu RS, Liu HC et al. Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization. Eur. J. Nucl. Med. 20, 339-344 (1993).
153. Markus HS, Lees AJ, Lennox G, Marsden CD, Costa DC. Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT: comparison with Parkinson's disease and normal controls. Mov. Disord. 10, 179-187 (1995).
154. 99mTc-HMPAO single-photon emission computed tomography study of Lewy body disease. J. Neurol. 244, 349-359 (1997).
155. 123I - CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur. J. Nucl. Med. 24, 320-325 (1997).
156. 99mTc-HMPAO SPECT in the investigation of dementia? J. Neurol. Neurosurg. Psychiatry 64, 306-313 (1998).
157. Defebvre LJ, Leduc V, Duhamel A et al. Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer's disease and idiopathic Parkinson's disease. J. Nucl. Med. 40, 956-962 (1999).
158. Cummings JL. Depression and Parkinson's disease:a review. Am. J. Psychiatry 149, 443-454 (1992).
159. Koller WC. Sensory symptoms in Parkinson's disease. Neurology 34, 957-959 (1984).
160. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup ofidiopathic parkinsonism. Neurology 36, 1130-1133 (1986).
161. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neuologic signs, disease stage, or disease duration. Neurology 38, 1237-1244 (1988).
162. Doty RL, Riklan M, Deems DA, Reynolds C, Stellar S The olfactory and cognitive deficits of Parkinson's disease: evidence for independence. Ann. Neurol. 25, 166-171 (1989).
163. Ward CD, Duvoisin RC, Ince SE et al. Parkinson's disease in twins. Adv. Neurol. 40, 341-344 (1984).
164. 123I] MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53, 1020-1025 (1999).
165. Courbon F, Brefel-Courbon C, Thalamas C et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov. Disord. 18, 890-897 (2003).
166. 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann. Nucl. Med. 18, 453-461(2004).
167. 123I-MIBG uptake in Parkinson's disease. Acta Neurol. Scand. 97, 303-306 (1998).
168. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 metaiodobenzylguanidine myocardial scintigraphy. J. Neurol. Sci. 155, 60-67 (1998).
169. Taki J, Nakajima K, Hwang EH et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur. J. Nucl. Med. 27, 566-573 (2000).
170. 123I] MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53, 1020-1025 (1999).
171. 123I- metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67, 189-194 (1999).
172. Druschky A, Hilz MJ, Platsch G et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J. Neurol. Sci. 175, 3-12 (2000).
173. Takatsu H, Nishida H, Matsuo H et al. Cardiac sympathetic
174. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 76, 249-251 (2005).
175. Spiegel J, Hellwig D, Farmakis G et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov. Disord. 15, 1004-1008 (2007).
176. Schneider SA, Edwards MJ, Mir P et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov. Disord. 22, 2210-2215 (2007).
177. 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov. Disord. 13, 438-445 (1998).
178. Vaamonde J, Ibáñez R, García AM, Poblete V. Study of the pre and postsynaptic dopaminergic system by DaTSCAN/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients. Neurologia 19, 292-300 (2004).
179. 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J. Neural Transm. 112, 677-692 (2005).
180. 123I]FP-CIT SPECT study. Eur. J. Nucl. Med. Mol. Imaging 34, 502-507 (2007).